| Detected | Trial | Change |
|---|---|---|
| 2026-06-12 | NCT07012044 A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With… |
Trial sites expanded: 2 -> 5 locations |
| 2026-06-12 | NCT03041688 Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and… |
date change Primary completion pushed: 2026-06-30 -> 2027-06-30 |
| 2026-06-12 | NCT03041688 Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and… |
date change Completion pushed: 2026-06-30 -> 2027-06-30 |
| 2026-06-06 | NCT04188405 Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia… |
Trial completed |
| 2026-06-06 | NCT04188405 Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia… |
date change Primary completion moved earlier: 2026-11-30 -> 2026-06-02 |
| 2026-06-06 | NCT04188405 Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia… |
date change Completion moved earlier: 2026-11-30 -> 2026-06-02 |
| 2026-05-28 | NCT06177171 Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated… |
Sponsor changed: Pamela Munster -> Varun Monga, MBBS |
| 2026-05-28 | NCT07012044 A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With… |
Primary endpoint(s) modified |
| 2026-05-20 | NCT07012044 A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With… |
date change Primary completion pushed: 2027-01-01 -> 2027-03-31 |
| 2026-05-20 | NCT07012044 A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With… |
date change Completion pushed: 2027-01-01 -> 2027-03-31 |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-06-01 | NCT07617363 ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk… | Phase 1 | Not Yet Recruiting |
| 2026-05-19 | NCT07594899 AI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCL | Phase 2 | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT07555405 | Evaluating the Safety and Efficacy of Decitabine in the Treatment of XMEN Patients | MAGT1 Deficiency | Not Yet Recruiting |
| Phase 3 | |||
| NCT05586074 | HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML | Leukemia, Acute Myeloid (AML) | Recruiting |
| Phase 2/3 | |||
| NCT04256317 | A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone… | Myelodysplastic Syndromes | Recruiting |
| Phase 2 | |||
| NCT05184842 | Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and… | Myelodysplastic Syndromes | Recruiting |
| NCT04872543 | A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST) | Malignant Peripheral Nerve Sheath Tumors (MPNST) | Recruiting |
| NCT01515527 | Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With… | Leukemia | Recruiting |
| NCT06511882 | Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD | Acute Myeloid Leukemia | Recruiting |
| NCT07148947 | Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic… | Accelerated Phase Myeloproliferative Neoplasm | Recruiting |
| NCT04282187 | Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of… | Acute Myeloid Leukemia | Recruiting |
| NCT06561074 | A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined… | T-cell Acute Lymphoblastic Leukemia | Recruiting |
| NCT05796570 | A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant… | Acute Myeloid Leukemia | Recruiting |
| NCT00801489 | Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin… | Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 | Recruiting |
| NCT03418038 | Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma… | Clonal Cytopenia of Undetermined Significance | Recruiting |
| NCT05201066 | Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab… | Myelodysplastic Syndromes | Active, Not Recruiting |
| NCT07060001 | Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia… | Acute Myeloid Leukemia (AML) | Not Yet Recruiting |
| NCT07505160 | Efficacy and Safety of Lisafotoclax Plus Decitabine and Homoharringtonine in… | Acute Myeloid Leukemia (AML) | Not Yet Recruiting |
| NCT02957968 | Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced… | Breast Adenocarcinoma | Active, Not Recruiting |
| NCT03164057 | A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia | Acute Myeloid Leukemia | Active, Not Recruiting |
| NCT01627041 | Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute… | Acute Myeloid Leukemia | Active, Not Recruiting |
| NCT00095784 | Decitabine in Treating Patients With Myelofibrosis | Primary Myelofibrosis | Active, Not Recruiting |
| NCT07594899 | AI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCL | Large B-Cell Lymphoma (LBCL) | Not Yet Recruiting |
| Phase 1/2 | |||
| NCT03661307 | Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or… | Acute Myeloid Leukemia | Recruiting |
| NCT02961101 | Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or… | Malignancies Multiple | Recruiting |
| NCT04742634 | Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable… | Myelodysplastic Syndromes | Recruiting |
| NCT04061421 | Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap… | MDS/MPN | Recruiting |